Eli Lilly has publicly stated that retatrutide — its next-generation obesity medicine — is more powerful than both Zepbound and Wegovy, based on the latest Phase 3 clinical trial data. As reported by NPR, Lilly announced that participants in the retatrutide trial lost an average of approximately 70 pounds over 80 weeks — a figure that has captured the attention of clinicians, researchers, and patients navigating the current landscape of obesity treatment.
The data anchor for this announcement is the TRIUMPH-4 Phase 3 trial, a 68-week randomized study evaluating retatrutide at doses up to 12mg once weekly. The headline result: participants receiving the 12mg dose achieved a mean body weight reduction of 28.7% — the highest mean weight loss ever recorded in a Phase 3 obesity clinical trial. To put that in practical terms, a person starting at 250 pounds could expect to lose, on average, more than 70 pounds. That is not a projection or a best-case scenario; that is the mean across the trial population.
Retatrutide (LY3437943, developed by Eli Lilly and Company) is a triple hormone receptor agonist, meaning it simultaneously activates three distinct receptors: GLP-1, GIP, and glucagon. This triple mechanism sets it apart from currently approved medications. Semaglutide (Wegovy) targets GLP-1 alone. Tirzepatide (Zepbound) targets GLP-1 and GIP. Retatrutide adds glucagon receptor activation to the mix — a feature that appears to meaningfully amplify both metabolic rate and the degree of weight loss achievable. In patient communities, the drug is commonly referred to as reta, and the triple receptor mechanism has earned the informal shorthand triple G among those following its development closely.
The TRIUMPH-4 titration schedule was designed with tolerability in mind: participants started at 2mg for weeks 1–4, escalated to 4mg (weeks 5–8), then 6mg (weeks 9–12), then 9mg (weeks 13–16), before reaching the 12mg maintenance dose at week 17 and beyond. This gradual ramp is intended to minimize gastrointestinal side effects — the most common of which, as seen in earlier Phase 2 data, include nausea, diarrhea, and vomiting, particularly during dose escalation.
The comparison between retatrutide, tirzepatide (Zepbound), and semaglutide (Wegovy) is now a central conversation in obesity medicine. The Phase 3 data for each drug was collected under different trial designs, so direct head-to-head comparisons must be interpreted carefully — but the numbers are nonetheless instructive.
| Drug | Mechanism | Trial | Duration | Mean Weight Loss (Highest Dose) |
|---|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 agonist | STEP-1 | 68 weeks | ~14.9% |
| Tirzepatide (Zepbound) | GLP-1 / GIP dual agonist | SURMOUNT-1 | 72 weeks | ~20.9% (15mg) |
| Retatrutide (reta) | GLP-1 / GIP / Glucagon triple agonist | TRIUMPH-4 | 68 weeks | ~28.7% (12mg) |
The Phase 2 data published in the New England Journal of Medicine (Jastreboff et al., 2023) had already hinted at this trajectory. In that 48-week trial (NCT04881760), participants receiving 8mg retatrutide lost a mean of 22.8% of body weight, while those on 12mg lost 24.2%. Notably, 100% of participants in the 8mg group achieved at least 5% weight loss — a benchmark that defines meaningful clinical response. Nearly half (48%) of participants on 12mg lost 25% or more of their body weight, and 64% lost at least 20%.
Beyond the scale, the Phase 2 cardiometabolic data were compelling. At 24 weeks, triglycerides fell by up to 39.3% across higher dose groups, and total cholesterol dropped by up to 17.7%. LDL cholesterol decreased by as much as 16.9% in the 8mg group. These are not trivial improvements — for patients who experience what is often described as food noise (the persistent mental preoccupation with eating and caloric seeking), retatrutide's glucagon component may be driving a level of appetite and metabolic regulation not previously achievable with single- or dual-agonist therapies.
The TRIUMPH-4 Phase 3 trial did reveal meaningful tolerability signals that deserve transparent discussion. Discontinuation rates were higher than placebo: 12.2% in the 9mg group and 18.2% in the 12mg group, compared to just 4.0% with placebo. Some discontinuations were attributed to perceived excessive weight loss — an unusual finding in obesity pharmacology. Dysesthesia (abnormal skin sensations) was reported in 20.9% of 12mg participants versus 0.7% on placebo, consistent with an elevated signal seen at 12mg in Phase 2 as well. These figures matter for shared clinical decision-making, and they will be examined more closely when the peer-reviewed Phase 3 publication becomes available — which, as of April 2026, remains pending.
As of April 2026, Eli Lilly has not yet filed a New Drug Application (NDA) with the FDA for retatrutide, and no FDA approval timeline has been publicly confirmed. The peer-reviewed publication of the TRIUMPH-4 Phase 3 data is also still pending. These are important regulatory and scientific milestones that must occur before retatrutide can become commercially available in the United States.
What is clear is that the clinical development program is advancing. The Phase 2 trial has concluded enrollment and treatment. The Phase 3 TRIUMPH-4 trial has been completed at 68 weeks. The next steps — NDA submission, FDA review, and potential approval — typically involve a timeline measured in months to years rather than weeks. Patients and clinicians are watching this process carefully, given that the 28.7% mean weight loss at 12mg represents a genuine paradigm shift in what pharmacotherapy can achieve for obesity.
For context, retatrutide was studied in adults with a BMI of 30 or higher, or 27 or higher with a weight-related comorbidity such as hypertension or dyslipidemia. The Phase 2 trial excluded individuals with type 2 diabetes. Subgroup analyses from Phase 2 showed that weight loss results were consistent across male and female participants and across BMI categories below and above 35 — suggesting broad applicability if the drug ultimately receives approval.
Quality of life data from Phase 2 (SF-36v2 scores) also showed meaningful improvement across all active dose groups at week 48, reinforcing that the clinical benefit extends beyond the number on the scale.
If retatrutide is on your radar — whether because current therapies have not delivered adequate results, because your BMI and metabolic profile suggest you may be a candidate, or because you simply want to stay informed as this drug moves through the regulatory process — joining the waitlist at glp3md.com is the best way to stay ahead of the curve. glp3md is a dedicated retatrutide information and waitlist platform built to help patients track the latest clinical developments and be positioned to act when availability changes. Joining the waitlist does not guarantee access to medication, a prescription, or any form of treatment — retatrutide is not FDA-approved, and no promises are made regarding future availability. What it does provide is a direct line to accurate, clinically grounded information as the science continues to unfold. Visit glp3md.com to add your name today.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.